Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

Scientists at Duke-NUS Medical School have identified a molecular “switch” that determines whether pancreatic cancer cells resist chemotherapy or respond to it—a finding that could help convert some ...

TD Cowen 46th Annual Health Care Conference March 2, 2026 9:10 AM ESTCompany ParticipantsJeffrey Poulton - CFO ...

Protein S deficiency represents a rare but significant hereditary thrombophilia that poses substantial risks during pregnancy, yet clinical management ...

NASOIE convenes top-tier clinicians to exchange advanced methodology in interventional endocrinology. At the event, Baird Medical engaged in discussions with attending physicians regarding the ...

Protein S deficiency represents a rare but significant hereditary thrombophilia that poses substantial risks during pregnancy ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

The proposed takeover of Warner Bros by Paramount could reshape Hollywood, movie theatres and the wider media landscape.

In a shocking twist after a monthslong bidding war, Paramount has emerged as the apparent victor in the fight to acquire Warner Bros. Netflix, who backed away from the deal Thursday, had hoped to win ...

Warner Bros., among the most filmmaker friendly studios operating, has had a banner year with major blockbusters and critical ...